61276-17-3
61276-17-3 结构式
基本信息
毛蕊花甙
麦角甾苷
类叶升麻苷
KUSAGININ
ACTEOSIDE
Acetoside
NSC 603831
Russetinol
Verbacoside
VERBASCOSIDE
StereosperMin
ISOVERBASCOSIDE
Verbascoside ,98%
VERBASCOSIDE WITH HPLC
Acteoside(Verbascoside)
Verbascoside(Acteoside)
Distinctive PhytosteM Lilac
3,4-Dihydroxyphenethyl alcohol acteoside
Extract from Verbena minutiflora (B864379)
Verbascoside, froM Cistanche deserticola Y.C.Ma
4-(3-(3,4-dihydroxyphenyl)-2-propenoate),(e)-beta-d-yl)
glucopyranoside,2-(3,4-dihydroxyphenyl)ethyl3-o-(6-deoxy-alpha-l-mannopyranos
2-(3,4-Dihydroxyphenyl)ethyl 3-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside 4-[(E)-3-(3,4-dihydroxyphenyl)propenoate]
B-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-O-(6-DEOXY-ALPHA-L-MANNOPYRANOSYL)-,4-[3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE],(E)-
ACTEOSIDE :B-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-O-(6-DEOXY-A-L-MANNOPYRANOSYL)-,4-[3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE],(E)-,
[(2R,3R,4R,5R,6R)-6-[2-(3,4-Dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Verbascoside [(2R,3R,4R,5R,6R)-6-[2-(3,4-Dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
物理化学性质
安全数据
常见问题列表
|
PKC 25 μM (IC 50 ) |
Verbascoside acts as an ATP-competitive inhibitor of PKC, with an IC 50 of 25 µM. Verbascoside shows K i s of 22 and 28 µM with respect to ATP and histone, respectively. Verbascoside has potent antitumor activity against L-1210 cells, with an IC 50 of 13 µM. Verbascoside (5, 10 µM) suppresses 2,4-dinitrochlorobenzene (DNCB)-induced T cell costimulatory factors CD86 and CD54, proinflammatory cytokines, and NFκB pathway activation in THP-1 cells.
Verbascoside (1%) reduces the overall scratching behavior incidence as well as the severity of the skin lesions in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mice model. Verbascoside also blocks DNCB-induced expression of proinflammatory cytokine TNF-α, IL-6, and IL-4 mRNA in skin lesions. Verbascoside (50, 100 mg/kg, i.p.) does not modify chronic constriction injury (CCI)-induced cold allodynia. Verbascoside (200 mg/kg, i.p.) decreases hyper-sensitivity to cold stimulus, acetone, on day 3 in rats. Verbascoside also significantly reduces behavioral changes associated with neuropathy. Moreover, Verbascoside decreases Bax and increases Bcl-2 on day 3.